The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Strategies for reversing drug resistance
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Bcl-2 Protein Family: Arbiters of Cell Survival
Adams, J. M., & Cory, S. (1998) · Science · doi:10.1126/science.281.5381.1322 · Cited by 5,332
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037 · cited 1×
“The first of these to be identified, the multidrug resistance-associated protein 1 (MRP1 or ABCC1) is similar to Pgp in several respects (Cole et al., 1992).”
Backgroundp53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
A model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
PUMA, a Novel Proapoptotic Gene, Is Induced by p53
Nakano, K., & Vousden, K. H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00214-3 · Cited by 2,315
Noxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., & Tanaka, †. N. (2000) · Science · doi:10.1126/science.288.5468.1053 · Cited by 2,112
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
A family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751
Griffith, O. W., & Meister, A. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35980-5 · Cited by 1,683
Smit, J. J. M., Schinkel, A. H., Elferink, R. P. J. O., Groen, A. K., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., Ottenhoff, R., van der Lugt, N. M. T., van Roon, M. A., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90380-9 · Cited by 1,456
Reed, J. C. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64779-7 · Cited by 1,288
PUMA Induces the Rapid Apoptosis of Colorectal Cancer Cells
Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W., & Vogelstein, B. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00213-1 · Cited by 1,280
An Information-Intensive Approach to the Molecular Pharmacology of Cancer
Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., et al. (1997) · Science · doi:10.1126/science.275.5298.343 · Cited by 1,183
Self-citationOda, K., Arakawa, H., Tanaka, T., Matsuda, K., Tanikawa, C., Mori, T., Nishimori, H., Tamai, K., Tokino, T., Nakamura, Y., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00073-8 · Cited by 1,172
Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,101
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Ueda, K., Cardarelli, C., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.9.3004 · Cited by 1,063
Godwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C., & Anderson, M. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.3070 · Cited by 925
Induction of the growth inhibitor IGF-binding protein 3 by p53
Buckbinder, L., Talbott, R., Velasco-Miguel, S., Takenaka, I., Faha, B., Seizinger, B. R., & Kley, N. (1995) · Nature · doi:10.1038/377646a0 · Cited by 869
Structural and biochemical basis of apoptotic activation by Smac/DIABLO
Chai, J., Du, C., Wu, J.-W., Kyin, S., Wang, X., & Shi, Y. (2000) · Nature · doi:10.1038/35022514 · Cited by 864
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799
Wild-Type Human p53 and a Temperature-Sensitive Mutant Induce Fas/APO-1 Expression
Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W.-W., Kruzel, E., et al. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3032 · Cited by 734
Active outward transport of daunomycin in resistant ehrlich ascites tumor cells
Danø, K. (1973) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(73)90191-0 · Cited by 723
Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer.
Roth, J. A., Nguyen, D., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Ferson, D. Z., Hong, W. K., Komaki, R., Lee, J. J., Nesbitt, J. C., et al. (1996) · Nature Medicine · doi:10.1038/nm0996-985 · Cited by 703
Müller, M., Meijer, C., Zaman, G. J., Borst, P., Scheper, R. J., Mulder, N. H., de Vries, E. G., & Jansen, P. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.13033 · Cited by 617
Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL
Degterev, A., Lugovskoy, A., Cardone, M., Mulley, B., Wagner, G., Mitchison, T., & Yuan, J. (2001) · Nature Cell Biology · doi:10.1038/35055085 · Cited by 550
Dai, J., Weinberg, R. S., Waxman, S., & Jing, Y. (1999) · Blood · doi:10.1182/blood.v93.1.268 · Cited by 540
Adenovirus-Mediated p53 Gene Transfer in Advanced Non-Small-Cell Lung Cancer
Swisher, S. G., Roth, J. A., Nemunaitis, J., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Connors, D. G., El-Naggar, A. K., Fossella, F., Glisson, B. S., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.9.763 · Cited by 496
Nemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., McCarty, T., Landers, S., Blackburn, A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.289 · Cited by 471
Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3
Tzung, S.-P., Kim, K. M., Basañez, G., Giedt, C. D., Simon, J., Zimmerberg, J., Zhang, K. Y. J., & Hockenbery, D. M. (2001) · Nature Cell Biology · doi:10.1038/35055095 · Cited by 452
Cretaceous age for the feathered dinosaurs of Liaoning, China
Swisher, C. C., Wang, Y.-Q., Wang, X.-L., Xu, X., & Wang, Y. (1999) · Nature · doi:10.1038/21872 · Cited by 420
List, A. F., Kopecky, K. J., Willman, C. L., Head, D. R., Persons, D. L., Slovak, M. L., Dorr, R., Karanes, C., Hynes, H. E., Doroshow, J. H., et al. (2001) · Blood · doi:10.1182/blood.v98.12.3212 · Cited by 419
Structural, mechanistic and clinical aspects of MRP1
Hipfner, D. R., Deeley, R. G., & Cole, S. P. C. (1999) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(99)00168-6 · Cited by 412
The Murine CAR Homolog Is a Receptor for Coxsackie B Viruses and Adenoviruses
Bergelson, J. M., Krithivas, A., Celi, L., Droguett, G., Horwitz, M. S., Wickham, T., Crowell, R. L., & Finberg, R. W. (1998) · Journal of Virology · doi:10.1128/jvi.72.1.415-419.1998 · Cited by 359
Pidd, a new death-domain–containing protein, is induced by p53 and promotes apoptosis
Lin, Y., Ma, W., & Benchimol, S. (2000) · Nature Genetics · doi:10.1038/79102 · Cited by 353
Strathdee, G., MacKean, M. J., Illand, M., & Brown, R. (1999) · Oncogene · doi:10.1038/sj.onc.1202540 · Cited by 350
Cancer gene therapy: fringe or cutting edge?
McCormick, F. (2001) · Nature Reviews Cancer · doi:10.1038/35101008 · Cited by 346
Fakhrai, H., Dorigo, O., Shawler, D. L., Lin, H., Mercola, D., Black, K. L., Royston, I., & Sobol, R. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2909 · Cited by 334
Fechner, H., Haack, A., Wang, H., Wang, X., Eizema, K., Pauschinger, M., Schoemaker, R. G., van Veghel, R., Houtsmuller, A. B., Schultheiss, H.-P., et al. (1999) · Gene Therapy · doi:10.1038/sj.gt.3301030 · Cited by 310
Therapeutic cancer targeting peptides
Aina, O. H., Sroka, T. C., Chen, M., & Lam, K. S. (2002) · Peptide Science · doi:10.1002/bip.10257 · Cited by 308
Dependence of transcriptional repression on CpG methylation density.
Hsieh, C. L. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.8.5487 · Cited by 300
ABC transporters in lipid transport
Borst, P., Zelcer, N., & van Helvoort, A. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00053-6 · Cited by 300
Lum, B. L., Kaubisch, S., Yahanda, A. M., Adler, K. M., Jew, L., Ehsan, M. N., Brophy, N. A., Halsey, J., Gosland, M. P., & Sikic, B. I. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.10.1635 · Cited by 299
Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR
de Bruin, M., Miyake, K., Litman, T., Robey, R., & Bates, S. E. (1999) · Cancer Letters · doi:10.1016/s0304-3835(99)00182-2 · Cited by 298
Self-citationRole of the Glutathione Redox Cycle in Acquired and de Novo Multidrug Resistance
Kramer, R. A., Zakher, J., & Kim, G. (1988) · Science · doi:10.1126/science.3399900 · Cited by 295
Oblimersen Bcl-2 Antisense: Facilitating Apoptosis in Anticancer Treatment
Klasa, R. J., Gillum, A. M., Klem, R. E., & Frankel, S. R. (2002) · Antisense and Nucleic Acid Drug Development · doi:10.1089/108729002760220798 · Cited by 280
Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.
List, A. F., Spier, C., Greer, J., Wolff, S., Hutter, J., Dorr, R., Salmon, S., Futscher, B., Baier, M., & Dalton, W. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.9.1652 · Cited by 274
Brown, R., Hirst, G. L., Gallagher, W. M., McIlwrath, A. J., Margison, G. P., van der Zee, A. G., & Anthoney, D. A. (1997) · Oncogene · doi:10.1038/sj.onc.1201167 · Cited by 243
Antisense therapy in oncology: new hope for an old idea?
Tamm, I., Dörken, B., & Hartmann, G. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05629-x · Cited by 229
Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance.
Bradshaw, D. M., & Arceci, R. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3674 · Cited by 223
Clinical trials of p-glycoprotein reversal in solid tumours
Ferry, D. R., Traunecker, H., & Kerr, D. J. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00091-3 · Cited by 214
Trump, D. L., Smith, D. C., Ellis, P. G., Rogers, M. P., Schold, S. C., Winer, E. P., Panella, T. J., Jordan, V. C., & Fine, R. L. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.23.1811 · Cited by 207
Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.
Bartlett, N. L., Lum, B. L., Fisher, G. A., Brophy, N. A., Ehsan, M. N., Halsey, J., & Sikic, B. I. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.4.835 · Cited by 189
Bailey, H. H., Mulcahy, R. T., Tutsch, K. D., Arzoomanian, R. Z., Alberti, D., Tombes, M. B., Wilding, G., Pomplun, M., & Spriggs, D. R. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.1.194 · Cited by 188
Fernández-Salas, E., Suh, K. S., Speransky, V. V., Bowers, W. L., Levy, J. M., Adams, T., Pathak, K. R., Edwards, L. E., Hayes, D. D., Cheng, C., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.11.3610-3620.2002 · Cited by 185
l-S,R-buthionine sulfoximine: historical development and clinical issues
Bailey, H. H. (1998) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(97)00164-6 · Cited by 178
Clinical Studies with Modulators of Multidrug Resistance
Fisher, G. A., & Sikic, B. I. (1995) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30099-6 · Cited by 163
Advani, R., Saba, H. I., Tallman, M. S., Rowe, J. M., Wiernik, P. H., Ramek, J., Dugan, K., Lum, B., Villena, J., Davis, E., et al. (1999) · Blood · doi:10.1182/blood.v93.3.787 · Cited by 158
Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane
Bourdon, J., Renzing, J., Robertson, P., Fernandes, K., & Lane, D. P. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200203006 · Cited by 147
Inhibitors of Multidrug Resistance to Antitumor Agents (MDR)
Avendaño, C., & Menéndez, J. C. (2002) · Current Medicinal Chemistry · doi:10.2174/0929867023371175 · Cited by 147
Rowinsky, E. K., Smith, L., Wang, Y. M., Chaturvedi, P. R., Villalona, M. A., Campbell, E., Aylesworth, C., Eckhardt, S. G., Hammond, L. A., Kraynak, M. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2964 · Cited by 146
The effect of verapamil on the pharmacokinetics of adriamycin
Kerr, D. J., Graham, J., Cummings, J., Morrison, J. G., Thompson, G. G., Brodie, M. J., & Kaye, S. B. (1986) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00273394 · Cited by 145
O’Neal, W. K., Zhou, H., Morral, N., Aguilar-Córdova, E., Pestaner, J. P., Langston, C., Mull, B. B., Wang, Y., Beaudet, A. L., & Lee, B. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.11-1587 · Cited by 135
Pharmacological considerations in the modulation of multidrug resistance
Fisher, G. A., Lum, B. L., Hausdorff, J., & Sikic, B. I. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00111-6 · Cited by 133
Germann, U. A., Ford, P. J., Shlyakhter, D., Mason, V. S., & Harding, M. W. (1997) · Anti-Cancer Drugs · doi:10.1097/00001813-199702000-00005 · Cited by 131
The p53 Tumor Suppressor Gene Inhibits Angiogenesis by Stimulating the Production of ThrombospondinPreprint
Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1994.059.01.053 · Cited by 123
Solary, É., Witz, B., Caillot, D., Moreau, P., Desablens, B., Cahn, J.-Y. Y., Sadoun, A., Pignon, B., Berthou, C., Maloisel, F., et al. (1996) · Blood · doi:10.1182/blood.v88.4.1198.bloodjournal8841198 · Cited by 109
Durant, S. T., Morris, M. M., Illand, M., McKay, H. J., McCormick, C., Hirst, G. L., Borts, R. H., & Brown, R. E. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80047-5 · Cited by 100
Sparreboom, A., Planting, A. S. T., Jewell, R. C., van der Burg, M. E., van der Gaast, A., de Bruijn, P., Loos, W. J., Nooter, K., Chandler, L. H., Paul, E. M., et al. (1999) · Anti-Cancer Drugs · doi:10.1097/00001813-199909000-00005 · Cited by 94
Wilson, W. H., Jamis‐Dow, C., Bryant, G., Balis, F. M., Klecker, R. W., Bates, S. E., Chabner, B. A., Steinberg, S. M., Köhler, D., & Wittes, R. E. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.1985 · Cited by 94
Self-citationOral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study
Millward, M. J., Cantwell, B. M. J., Munro, N. C., Robinson, A. G., Corris, P. A., & Harris, A. L. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.189 · Cited by 91
Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs
Sorrentino, B. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc823 · Cited by 90
Kornblau, S. M., Estey, E. H., Madden, T. L., Tran, H. T., Zhao, S., Consoli, U., Snell, V., Sanchez‐Williams, G., Kantarjian, H. M., Keating, M. J., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1796 · Cited by 89
Lee, E. J., George, S. L., Caligiuri, M. A., Szatrowski, T. P., Powell, B. L., Lemke, S., Dodge, R. K., Smith, R. D., Baer, M. R., & Schiffer, C. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2831 · Cited by 87
Heere‐Ress, E., Thallinger, C., Lucas, T., Schlagbauer‐Wadl, H., Wacheck, V., Monia, B. P., Wolff, K. S., Pehamberger, H., & Jansen, B. (2002) · International Journal of Cancer · doi:10.1002/ijc.10248 · Cited by 85
Does the Antitumor Adenovirus ONYX-015/dl1520 Selectively Target Cells Defective in the p53 Pathway?
Dix, B. R., Edwards, S. J., & Braithwaite, A. W. (2001) · Journal of Virology · doi:10.1128/jvi.75.12.5443-5447.2001 · Cited by 85
Momparler, R. L., Côté, S., & Eliopoulos, N. (1997) · Leukemia · doi:10.1038/sj.leu.2400550 · Cited by 70
Stewart, A. J., Canitrot, Y., Baracchini, E., Dean, N. M., Deeley, R. G., & Cole, S. P. C. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02220-1 · Cited by 66
Robey, R. W., Bakke, S., Stein, W. D., Meadows, B., Litman, T., Patil, S., Smith, T., Fojo, T., & Bates, S. E. (1999) · Blood · doi:10.1182/blood.v93.1.306 · Cited by 64
Self-citationLai, G., Moscow, J. A., Alvarez, M. G., Fojo, A. T., & Bates, S. E. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490511 · Cited by 64
Self-citationBenderra, Z., Trussardi‐Régnier, A., Morjani, H., VILLA, A. M., Doglia, S. M., & Manfait, M. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00288-9 · Cited by 61
Relling, M. V. (1996) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199608000-00006 · Cited by 60
Pharmacokinetics of vincristine in cancer patients treated with nifedipine
FEDELI, L., Colozza, M., Boschetti, E., Sabalich, I., Aristei, C., Guerciolini, R., Favero, A. D., Rossetti, R., Tonato, M., Rambotti, P., et al. (1989) · Cancer · Cited by 55
Barton, C. M., & Lemoine, N. R. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.88 · Cited by 52
Kowalski, P., Stein, U., Scheffer, G. L., & Lage, H. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700471 · Cited by 51
Lorico, A., Bertola, A., Baum, C., Fodstad, Ø., & Rappa, G. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6489 · Cited by 46
Interactions of antimitotic peptides and depsipeptides with tubulin
Hamel, E. (2002) · Biopolymers · doi:10.1002/bip.10255 · Cited by 45
Reversal of Cisplatin and Multidrug Resistance by Ribozyme-Mediated Glutathione Suppression
Nagata, J., Kijima, H., Hatanaka, H., et al. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5399 · Cited by 41
Gao, Z., Gao, Z., Gao, Z., Gao, Z., Fields, J. Z., & Boman, B. M. (1999) · International Journal of Cancer · Cited by 34
The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer
Rizk, N. P., Chang, M. Y., Kouri, C. E., Seth, P. K., Kaiser, L. R., Albelda, S. Μ., & Amin, K. M. (1999) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700059 · Cited by 31
Olie, R. A., & Zangemeister‐Wittke, U. (2001) · Drug Resistance Updates · doi:10.1054/drup.2001.0181 · Cited by 27
Vahrmeijer, A. L., Hoetelmans, R. W. M., Mulder, G. J., Schutrups, J., van Vlierberghe, R. L. P., van de Velde, C. J. �., & van Dierendonck, J. H. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00286-0 · Cited by 25
Tango, Y., Fujiwara, T., Itoshima, T., Takata, Y., Katsuda, K., Uno, F., Ohtani, S., Tani, T., Roth, J. A., & Tanaka, N. (2002) · Human Gene Therapy · doi:10.1089/104303402760128595 · Cited by 25
Anti-oncogene Ribozymes for Cancer Gene Therapy
Irie, A., Kijima, H., Ohkawa, T., Bouffard, D. Y., Suzuki, T., Curcio, L. D., Holm, P. S., Sassani, A., & Scanlon, K. J. (1997) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60141-6 · Cited by 21
Inhibition of glucose transporter gene expression by antisense nucleic acids in HL-60 leukemia cells
Chan, J. Y., Kong, S., Choy, Y.-M., Lee, C.-Y., & Fung, K. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00219-2 · Cited by 19
Cited by
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Glutathione in Cancer Biology and Therapy
Estrela, J. M., Ortega, A., & Obrador, E. (2006) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360500523878 · Cited by 1,041
Modulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Role of Reactive Oxygen Species (ROS) in Therapeutics and Drug Resistance in Cancer and Bacteria
Dharmaraja, A. T. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01243 · Cited by 582
Nrf2 Enhances Cell Proliferation and Resistance to Anticancer Drugs in Human Lung Cancer
Homma, S., Ishii, Y., Morishima, Y., Yamadori, T., Matsuno, Y., Haraguchi, N., Kikuchi, N., Satoh, H., Sakamoto, T., Hizawa, N., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2822 · Cited by 418
Metadata
- Authors
- Fojo, T., & Bates, S.
- Venue
- Oncogene
- Published
- 2003-10-20
- Volume
- 22
- Issue
- 47
- Pages
- 7512-7523
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2074525949
- Cited by
- 357
- References
- 98
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.